Paediatric Intensive Care Unit, Centre Hospitalier Universitaire, Caen, France; Medical School, Université Caen Normandie, Caen, France; Centre Hospitalier Universitaire, Université de Lille, ULR 2694-METRICS: Évaluation des technologies de santé et des pratiques médicales, Lille, France.
Department of Pharmacy, University Hospital of Caen, Caen, France.
Lancet Child Adolesc Health. 2024 Mar;8(3):236-244. doi: 10.1016/S2352-4642(23)00288-2. Epub 2024 Jan 12.
Intravenous maintenance fluid therapy (IV-MFT) is one of the most prescribed, yet one of the least studied, interventions in paediatric acute and critical care settings. IV-MFT is not typically treated in the same way as drugs with specific indications, contraindications, compositions, and associated adverse effects. In the last decade, societies in both paediatric and adult medicine have issued evidence-based practice guidelines for the use of intravenous fluids in clinical practice. The main objective of this Viewpoint is to summarise and compare the rationales on which these international expert guidelines were based and how these recommendations affect IV-MFT practices in paediatric acute and critical care. Although these guidelines recommend the use of isotonic fluids as a standard in IV-MFT, some discrepancies and uncertainties remain regarding the systematic use of balanced fluids, glucose and electrolyte requirements, and appropriate fluid volume. IV-MFT should be considered in the same way as any other prescription drug and none of the components of IV-MFT prescription should be overlooked (ie, choice of drug, dosing rate, duration of treatment, and de-escalation). Furthermore, most evidence that was used to inform the guidelines comes from high-income countries. Although some principles of IV-MFT are universal, the direct relevance to and feasibility of implementing the guidelines in low-income and middle-income countries is uncertain.
静脉补液维持治疗(IV-MFT)是儿科急性和危重症治疗中最常开具但研究最少的干预措施之一。IV-MFT 通常不像具有特定适应证、禁忌证、成分和相关不良反应的药物那样得到同样的处理。在过去十年中,儿科和成人医学领域的学会都发布了有关静脉补液在临床实践中应用的基于证据的实践指南。本观点的主要目的是总结和比较这些国际专家指南所依据的原理,以及这些建议如何影响儿科急性和危重症治疗中的 IV-MFT 实践。尽管这些指南建议将等渗液作为 IV-MFT 的标准,但在平衡液的系统使用、葡萄糖和电解质需求以及适当的液体量方面仍存在一些差异和不确定性。IV-MFT 应被视为与任何其他处方药相同,并且不应忽视 IV-MFT 处方的任何组成部分(即药物选择、给药速度、治疗持续时间和降级)。此外,用于为指南提供信息的大多数证据均来自高收入国家。尽管 IV-MFT 的一些原则是普遍适用的,但在低收入和中等收入国家实施这些指南的直接相关性和可行性尚不确定。